The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Howard L Kaufman
Consultant or Advisory Role - Amgen
Robert Hans Ingemar Andtbacka
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Frances A. Collichio
Consultant or Advisory Role - Amgen
Research Funding - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Morphotek; Novartis
Thomas Amatruda
No relevant relationships to disclose
Neil N. Senzer
No relevant relationships to disclose
Jason Chesney
No relevant relationships to disclose
Keith A. Delman
Research Funding - Amgen
Lynn E. Spitler
Consultant or Advisory Role - Amgen
Igor Puzanov
Consultant or Advisory Role - Amgen
Yining Ye
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ai Li
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jennifer L. Gansert
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Robert Coffin
Consultant or Advisory Role - Amgen
Stock Ownership - BioVex
Merrick I. Ross
Consultant or Advisory Role - Amgen
Honoraria - Paradigm Medical Communications
Research Funding - Amgen